LONDON, June 30, 2014 /PRNewswire/ --
On Friday, June 27, 2014, the NASDAQ Composite ended at 4,397.93, up 0.43%, the Dow Jones Industrial Average edged 0.03% higher, to finish the day at 16,851.84, and the S&P 500 closed at 1,960.96, up 0.19%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 707.06, down 0.21%, while the index has advanced 4.44% in the previous three months. Investor-Edge has initiated coverage on the following equities: Insmed Inc. (NASDAQ: INSM), Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM), CytRx Corp. (NASDAQ: CYTR) and Celldex Therapeutics Inc. (NASDAQ: CLDX). Free technical research on INSM, PPHM, CYTR and CLDX can be downloaded upon signing up at:
http://www.investor-edge.com/4325-register
Insmed Inc.'s stock finished the Friday's session 0.98% higher at $19.51. A total of 1.18 million shares were traded, which was above its three months average volume of 1.09 million shares. The stock moved between $18.97 and $19.54 during the session. Over the last one month and the previous three months, Insmed Inc.'s shares have surged 47.13% and 13.89%, respectively. Additionally, from the beginning of 2014, the company's stock has gained an upside of 14.76%. The company's shares are trading above their 50-day and 200-day moving averages. Moreover, the stock's 200-day moving average of $16.26 is greater than its 50-day moving average of $14.37. Insmed Inc.'s stock has a Relative Strength Index (RSI) of 77.21. Sign up today to read free research on INSM at:
http://www.investor-edge.com/4325-INSM-30Jun2014.pdf
On Friday, shares in Peregrine Pharmaceuticals Inc. fluctuated between $1.83 and $1.92 before ending the session 3.78% higher at $1.92. Peregrine Pharmaceuticals Inc.'s stock reported a trading volume of 2.57 million shares, above its three months average volume of 1.62 million shares. Peregrine Pharmaceuticals Inc.'s shares have advanced 8.47% in the previous three trading sessions, 3.23% in the last three months and 38.13% on YTD basis. The stock is trading above its 50-day and 200-day moving averages of $1.79 and $1.65, respectively. Moreover, shares of the company have an RSI of 60.70. Sign up today to read free research on PPHM at:
http://www.investor-edge.com/4325-PPHM-30Jun2014.pdf
On Friday, CytRx Corp.'s stock declined 5.41%, to close the day at $4.02. The stock recorded a trading volume of 9.62 million shares, much above its three months average volume of 1.96 million shares. The stock oscillated between $3.98 and $4.27 during the session. Over the last one month and over the past three months, CytRx Corp.'s shares have gained 2.81% and 17.20%, respectively. However, the stock has lost 35.89% since the start of this year. The stock is trading above its 50-day moving average of $3.90, while the 50-day moving average is below CytRx Corp.'s 200-day moving average of $4.13. Additionally, the stock has an RSI of 41.70. Sign up today to read free research on CYTR at:
http://www.investor-edge.com/4325-CYTR-30Jun2014.pdf
On Friday, shares in Celldex Therapeutics Inc. recorded a trading volume of 1.68 million shares, lower than its three months average volume of 2.73 million shares. The stock ended the day at $16.62, which was 0.78% below its previous day's closing of $16.75, and registered an intraday range of $16.31 and $16.88. Although Celldex Therapeutics Inc.'s shares have surged 16.22% in the last one month, it has declined 1.74% in the previous three trading sessions and 31.35% on YTD basis. The company's stock is trading above its 50-day moving average of $14.87. Furthermore, shares of the company have an RSI of 54.37. Sign up today to read free research on CLDX at:
http://www.investor-edge.com/4325-CLDX-30Jun2014.pdf
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
http://www.investor-edge.com
SOURCE Investor-Edge
